RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Determining the SII can inform the design and clinical application of RAS-targeted therapies to improve tumor selectivity and therapeutic outcomes.
Authors
- Beau Baars (ORCID: https://orcid.org/0009-0002-7712-5314)
- Christos Adamopoulos (ORCID: https://orcid.org/0000-0001-6323-4216)
- Ziyue Kou (ORCID: https://orcid.org/0009-0009-2132-6505)
- Tiphaine C. Martin (ORCID: https://orcid.org/0000-0001-9990-1455)
- Evripidis Gavathiotis (ORCID: https://orcid.org/0000-0001-6319-8331)
- Stuart A. Aaronson (ORCID: https://orcid.org/0000-0002-4643-0474)
- Ana Orive‐Ramos
- Matthew J. Emmett (ORCID: https://orcid.org/0000-0002-8855-423X)
- William R. Sellers (ORCID: https://orcid.org/0000-0002-3539-9803)
- Shaomeng Wang (ORCID: https://orcid.org/0000-0002-8782-6950)
- Bijaya Gaire (ORCID: https://orcid.org/0000-0002-1600-4757)
- Poulikos I. Poulikakos (ORCID: https://orcid.org/0000-0001-6071-9963)
- Mathieu Desaunay (ORCID: https://orcid.org/0000-0001-8914-4892)
- Guangyan Li (ORCID: https://orcid.org/0009-0003-7246-9991)
Institutions
- Broad Institute (US)
- Albert Einstein College of Medicine (US)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Massachusetts General Hospital (US)
- Michigan United (US)
- Michigan Medicine (US)
- Dana-Farber Cancer Institute (US)
- Michigan Center for Translational Pathology (US)
- Michigan Cancer Research Consortium (US)
- Tisch Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Molecular Cancer Research
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1158/1541-7786.mcr-25-0319
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81